Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice (original) (raw)
Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380. ArticleCASPubMed Google Scholar
Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 2005; 90: 1617–1625. CASPubMed Google Scholar
Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918. CASPubMed Google Scholar
Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood 2011; 118: 5905–5913. ArticleCASPubMed Google Scholar
Konig H, Levis M . Targeting FLT3 to treat leukemia. Expert Opin Ther Targets 2015; 19: 37–54. ArticleCASPubMed Google Scholar
Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 2002; 16: 186–195. ArticleCASPubMed Google Scholar
Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012; 119: 388–398. ArticleCASPubMedPubMed Central Google Scholar
Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G . Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998; 17: 3714–3725. ArticleCASPubMedPubMed Central Google Scholar
Argiropoulos B, Palmqvist L, Yung E, Kuchenbauer F, Heuser M, Sly LM et al. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. Exp Hematol 2008; 36: 845–859. ArticleCASPubMed Google Scholar
Wang GG, Pasillas MP, Kamps MP . Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood 2005; 106: 254–264. ArticleCASPubMedPubMed Central Google Scholar
Palmqvist L, Pineault N, Wasslavik C, Humphries RK . Candidate genes for expansion and transformation of hematopoietic stem cells by NUP98-HOX fusion genes. PLoS One 2007; 2: e768. ArticlePubMedPubMed Central Google Scholar
Palmqvist L, Argiropoulos B, Pineault N, Abramovich C, Sly LM, Krystal G et al. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. Blood 2006; 108: 1030–1036. ArticleCASPubMed Google Scholar
Morgado E, Albouhair S, Lavau C . Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation. Blood 2007; 109: 4020–4022. ArticleCASPubMed Google Scholar
Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984–2992. ArticleCASPubMedPubMed Central Google Scholar
Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Dohner H, Dohner K, Schittenhelm MM . Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013; 12: 19. ArticleCASPubMedPubMed Central Google Scholar
Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY . Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood 2012; 120: 4049–4057. ArticleCASPubMed Google Scholar
McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95: 3489–3497. CASPubMed Google Scholar
Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002; 100: 238–245. ArticleCASPubMed Google Scholar
Brasel K, Escobar S, Anderberg R, de Vries P, Gruss HJ, Lyman SD . Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia 1995; 9: 1212–1218. CASPubMed Google Scholar
Lisovsky M, Braun SE, Ge Y, Takahira H, Lu L, Savchenko VG et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996; 10: 1012–1018. CASPubMed Google Scholar
Stirewalt DL, Radich JP . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650–665. ArticleCASPubMed Google Scholar
Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 2002; 99: 121–129. ArticleCASPubMed Google Scholar
Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Blood 2013; 121: 1422–1431. ArticleCASPubMedPubMed Central Google Scholar
Christensen JL, Weissman IL . Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci USA 2001; 98: 14541–14546. ArticleCASPubMedPubMed Central Google Scholar
Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 2008; 180: 7358–7367. ArticleCASPubMed Google Scholar
Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669–3676. ArticleCASPubMed Google Scholar
Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54–60. ArticleCASPubMed Google Scholar
Rathinam C, Thien CB, Flavell RA, Langdon WY . Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010; 18: 341–352. ArticleCASPubMed Google Scholar
Imamura T, Morimoto A, Takanashi M, Hibi S, Sugimoto T, Ishii E et al. Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement. Br J Haematol 2002; 119: 119–121. ArticleCASPubMed Google Scholar
Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM . The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia 2011; 25: 1239–1248. ArticleCASPubMed Google Scholar
Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593–5603. ArticleCASPubMed Google Scholar
Pineault N, Buske C, Feuring-Buske M, Abramovich C, Rosten P, Hogge DE et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 2003; 101: 4529–4538. ArticleCASPubMed Google Scholar
SB H, SR C, WS B, D G, TB N. Designing clinical research: an epidemiologic approach. 4th edn. 2013.